Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24452557 | 0.88 | NPC1 (0.65) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL31715213 | 0.86 | NPC1 (0.64) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL7105351 | 0.86 | NPC1 (0.64) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL31352277 | 0.85 | NPC1 (0.62) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL31352167 | 0.85 | NPC1 (0.62) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL1407148 | 0.84 | NPC1 (0.61) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL4242279 | 0.84 | NPC1 (0.61) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL4248164 | 0.84 | NPC1 (0.61) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL17292790 | 0.84 | NPC1 (0.61) | NPC1LMNAALDH1A1RAB9AKDM4E | |
| SCHEMBL31715204 | 0.84 | NPC1 (0.61) | NPC1LMNAALDH1A1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12384764-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-114787155-B | Pharmaceutical compounds | 辉瑞公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025002177-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 长春金赛药业有限责任公司 | 2025-01-02 | — | — | WO | disclosed |
| US-20220380349-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-12-01 | — | — | US | disclosed |
| CN-114787155-A | Pharmaceutical compounds | 瑞威有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021084280-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-05-06 | — | — | WO | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-1781661-A2 | VASOPRESSIN V1A ANTAGONISTS | Ferring B.V. (NL) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | NPC1 224/4885LMNA 2153/4885ALDH1A1 621/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | NPC1 480/4885LMNA 2715/4885ALDH1A1 3562/4885 |
| US-12384764-B2 | Pharmaceutical compounds | CNR1, HRH4, GABRA1 | NPC1 369/4885LMNA 2103/4885ALDH1A1 2411/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | NPC1 4072/4885LMNA 2881/4885ALDH1A1 902/4885 |
| US-20220380349-A1 | PHARMACEUTICAL COMPOUNDS | CNR1, HRH4, GABRA1 | NPC1 427/4885LMNA 2197/4885ALDH1A1 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.